ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022. A webcast of the pre-recorded presentation will be […]
Continue Reading